A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor
EMPHASIS-lung: Erlotinib MALDI TOF Phase III signature in squamous cell non-small cell lung cancer
In the EMPHASIS-lung trial, the potential of Veristrat, a clinically validated serum proteomic test, to predict response to treatment by erlotinib or docetaxel, was assessed in pre-treated patients with advanced squamous cell lung carcinoma.
Recruitment was terminated prematurely due to an accrual rate that was deemed insufficient and publication of controversial new data from another study. No safety concerns led to the decision to close accrual.
Trial Scheme
